Fresenius Medical Care Partners with JMS Co. Ltd. to advance home dialysis treatment in Japan

HONG KONG – (COMMERCIAL THREAD) – Fresenius Medical Care, the world’s leading provider of products and services for people with kidney disease, today announced a strategic distribution partnership with JMS Co. Ltd, a supplier of medical devices and pharmaceuticals, in Japan. Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care’s innovative home dialysis therapies in the Japanese market, providing patients with a wider range of dialysis choices to fit their lifestyle, improve their well-being and help meet the needs of Home health care of Japan’s aging population.

Japan has what is called a “super-aging society” with the largest population of elderly people in the world.1 By 2035, it is projected that 33% of the total population will be 65 years of age and over.1 Along with this accelerated aging, the number of people requiring dialysis in Japan continues to grow each year. At the end of 2018, there were 339,841 people on dialysis in Japan with an average age of almost 69 years.2 Yet the vast majority of these people receive their treatment at dialysis centers, with just 3 percent undergoing home dialysis – the lowest percentage of home dialysis users in the developed world.2 The combination of the increased aging of the population and the need for dialysis is putting pressure on the Japanese healthcare system, and it is obligatory for Japanese society to find a solution to these problems for sustainability.3

Expanding the possibilities for home dialysis has the potential to bring clinical benefits to patients, as well as offer greater flexibility in treatment that can improve quality of life.4 Home dialysis allows patients to benefit from treatment in the familiar environment of their home, where they can take an active role in their own care, while avoiding the need to visit a clinic – and thus benefit greater flexibility to work, study and / or socialize.4

“Fresenius Medical Care is committed to improving the quality of life for patients through our expertise in the management of chronic kidney disease,” said Harry de Wit, CEO and President of Fresenius Medical Care Asia Pacific. “By providing a variety of treatment options for healthcare professionals and patients, we aim to achieve our vision – to create a future worth living, for patients, around the world, every day.”

“We are happy to form this strategic partnership with JMS because we share the same vision for the future of home therapy in Japan. We are confident that our partnership will bring substantial benefits to the Japanese community, ”said Ms. Jean DeSombre, Executive Vice President for Mature Asia, Fresenius Medical Care Asia Pacific.

Under the agreement, JMS Co. Ltd. will distribute Fresenius Medical Care’s advanced portfolio of home dialysis systems in Japan, including the automatic peritoneal dialysis system. These systems, which have US Federal Drug Authority (FDA) approvals and the European CE mark, are widely used in other developed countries.


The references

  1. Iwata, H., Matsushima, M., Watanabe, T., Sugiyama, Y., Yokobayashi, K., Son, D., Satoi, Y., Yoshida, E., Satake, S., Hinata, Y. and Fujinuma, Y., 2020. The need for home physicians in Japan – 2020 to 2060. BMC Health Services Research, 20 (1), p.1-11.

  2. Nitta, K., Goto, S., Masakane, I., Hanafusa, N., Taniguchi, M., Hasegawa, T., Nakai, S., Wada, A., Hamano, T., Hoshino, J., Joki, N., Abe, M., Yamamoto, K. & Nakamoto, H., 2020. Dialysis Data Annual Report for 2018, JSDT Renal Data Registry: Survey Methods, Facility Data, Incidence, prevalence and mortality. Renal replacement therapy, 6 (1), p.1-18.

  3. Hanafusa, N. and Fukagawa, M., 2020. Global dialysis perspective: Japan. Kidney360, 1 (5), p.416-419.

  4. Walker, R., Howard, K. & Morton, R., 2017. Home hemodialysis: a comprehensive review of economic and patient-centered considerations. ClinicoEconomics and Outcome Research, Volume 9, pp. 149-161.


Fresenius Medical Care is the world’s leading provider of products and services for people with kidney disease, with approximately 3.7 million patients worldwide undergoing regular dialysis treatment. Through its network of more than 4,100 dialysis clinics, Fresenius Medical Care provides dialysis treatment to approximately 346,000 patients worldwide. Fresenius Medical Care is also the leading supplier of dialysis products such as dialysis machines or dialyzers. In addition to its core business, the Renal Care Continuum, the company is focusing on its expansion in complementary areas and in the field of intensive care. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS).

For more information, visit the company’s website at


This press release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts linked to the results of the COVID-19 pandemic. clinical studies, fluctuations in exchange rates, uncertainties in litigation or investigative procedures and the availability of funding. These and other risks and uncertainties are detailed in the reports of Fresenius Medical Care AG & Co. KGaA filed with the United States Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA assumes no responsibility for updating any forward-looking statements contained in this press release.

Source link

Leave a Reply

Your email address will not be published.